Pancreatic Cancer Research

ResearcherKansai Medical UniversityActive in the last 2 years

Takashi Hatori

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5109903270. Sources: OpenAlex.

Their work

Papers
15
Trials
0
Grants
0
Labs led
0
Collaborators
83
Papers, trials and grants by year

2011: 2 papers · 2012: 2 papers · 2013: 3 papers · 2014: 1 paper · 2015: 1 paper · 2016: none · 2017: 4 papers · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 15

  1. Clinical importance of suspicious for malignancy compared to positive for malignancy in peritoneal cytology for surgically resected pancreatic cancer. Co-author DOI 10.1016/j.pan.2025.05.006↗
  2. [Pancreas Bed Recurrence Resection Combined with Celiac and Common Hepatic Arterial Resection after Distal Pancreatectomy for Pancreatic Cancer]. Co-author PMID 29362327↗
  3. Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer. Co-author DOI 10.1007/s00432-017-2349-y↗
  4. Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study. Co-author DOI 10.1111/cas.13113↗
  5. Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic panc… Co-author DOI 10.1136/esmoopen-2016-000151↗
  6. Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer. Co-author DOI 10.1186/s13046-017-0509-1↗
  7. [Symptoms, clinical findings and laboratory data in the pancreatic ductal adenocarcinoma]. Co-author PMID 25856995↗
  8. EBM-based Clinical Guidelines for Pancreatic Cancer (2013) issued by the Japan Pancreas Society: a synopsis. Co-author DOI 10.1093/jjco/hyu127↗
  9. Clinical importance of Familial Pancreatic Cancer Registry in Japan: a report from kick-off meeting at International Symposium on Pancreas Cancer 2012. Co-author DOI 10.1007/s00534-013-0611-5↗
  10. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan… Co-author DOI 10.1200/jco.2012.43.3680↗
  11. Immunological responses to a multi-peptide vaccine targeting cancer-testis antigens and VEGFRs in advanced pancreatic cancer patients. Co-author DOI 10.4161/onci.27010↗
  12. Japan Pancreatic Cancer Registry; 30th year anniversary: Japan Pancreas Society. Co-author DOI 10.1097/mpa.0b013e318258055c↗
  13. Targeting of MAPK-associated molecules identifies SON as a prime target to attenuate the proliferation and tumorigenicity of pancreatic cancer cells. Co-author DOI 10.1186/1476-4598-11-88↗
  14. Pancreatic ductal adenocarcinoma derived from IPMN and pancreatic ductal adenocarcinoma concomitant with IPMN. Co-author DOI 10.1097/mpa.0b013e318215010c↗
  15. Impact of dihydropyrimidine dehydrogenase and γ-glutamyl hydrolase on the outcomes of patients treated with gemcitabine or S-1 as adjuvant chemotherapy for adv… Co-author DOI 10.3892/etm.2011.340↗

Closest collaborators

The 25 strongest of 83 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shinichi Egawa · 6 shared papers, 2012–2025 · strength 0.38
  2. Toru Furukawa · 4 shared papers, 2011–2025 · strength 0.28
  3. Takao Itoi · 2 shared papers, 2014–2025 · strength 0.22
  4. Sohei Satoi · 1 shared paper, 2025 · strength 0.19
  5. Noriyoshi Fukushima · 1 shared paper, 2025 · strength 0.19
  6. Yohei Masugi · 1 shared paper, 2025 · strength 0.19
  7. Yoshifumi Takeyama · 1 shared paper, 2025 · strength 0.19
  8. Kenichi Hirabayashi · 1 shared paper, 2025 · strength 0.19
  9. Haruyoshi Tanaka · 1 shared paper, 2025 · strength 0.19
  10. Yuichi Nagakawa · 1 shared paper, 2025 · strength 0.19
  11. Makoto Ueno · 1 shared paper, 2025 · strength 0.19
  12. Masaji Tani · 1 shared paper, 2025 · strength 0.19
  13. Michiaki Unno · 1 shared paper, 2025 · strength 0.19
  14. Tsutomu Fujii · 1 shared paper, 2025 · strength 0.19
  15. Masakazu Yamamoto · 4 shared papers, 2011–2015 · strength 0.19
  16. Takuji Okusaka · 5 shared papers, 2012–2017 · strength 0.19
  17. Masao Tanaka · 5 shared papers, 2011–2017 · strength 0.18
  18. Junji Furuse · 4 shared papers, 2013–2017 · strength 0.16
  19. Shinichi Ohkawa · 3 shared papers, 2013–2017 · strength 0.13
  20. Taketo Yamaguchi · 3 shared papers, 2013–2017 · strength 0.13
  21. Tatsuya Ioka · 3 shared papers, 2013–2017 · strength 0.13
  22. Narikazu Boku · 3 shared papers, 2013–2017 · strength 0.13
  23. Ann‐Lii Cheng · 3 shared papers, 2013–2017 · strength 0.13
  24. Akihiro Funakoshi · 3 shared papers, 2013–2017 · strength 0.13
  25. Yasuo Ohashi · 3 shared papers, 2013–2017 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.